Summary and conclusion
Symptoms of anxiety and post-traumatic stress are going to be prevalent
as a consequence of the COVID-19 pandemic, particularly in those most
closely affected by the disease, and in those with existing anxiety
conditions. Current anti-anxiety medications possess significant
unwanted side-effects, including
strong drug dependence and
withdrawal syndromes. CBD is already being evaluated as a potential
treatment during the active coronavirus disease phase, and we suggest
that the preclinical and clinical evidence base supports the hypothesis
that CBD could be a novel pharmacological option for treating
COVID-related anxiety disorders. CBD could be more preferable compared
to some of the medicines currently available with respect to its safety
and side effect profile.